First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: Safety, biodistribution, and preliminary clinical findings

Molecular Therapy

Volumn 23, Issue 4, 2015, Pages 779-789

  Buscail, Louis ^a,b,c   Bournet, Barbara ^a,b   Vernejoul, Fabienne ^d   Cambois, Gilles ^d   Lulka, Hubert ^b   Hanoun, Naïma ^b   Dufresne, Marlène ^b   Meulle, Aline ^b   Vignolle Vidoni, Alix ^a,b   Ligat, Laetitia ^b   Saint Laurent, Nathalie ^b   Pont, Frédéric ^b   Dejean, Sébastien ^e   Gayral, Marion ^b   Martins, Frédéric ^f   Torrisani, Jérôme ^b   Barbey, Odile ^c   Gross, Fabian ^c   Guimbaud, Rosine ^a,b   Otal, Philippe ^a,b   Lopez, Frédéric ^b   Tiraby, Gérard ^d   Cordelier, Pierre ^b   more..

^a CHU RANGUEIL   (France)

^b CANCER RESEARCH CENTER OF TOULOUSE   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d Zone industrielle de Montaudran   (France)

^e UNIVERSITÉ PAUL SABATIER   (France)

^f University Hospital of Toulouse   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CA 19-9 ANTIGEN; CYL 02; GEMCITABINE; GENE THERAPY AGENT; MESSENGER RNA; MICRORNA; MICRORNA 122; MICRORNA 145; MICRORNA 150; MICRORNA 185; MICRORNA 21; MICRORNA 320; MICRORNA 335; MICRORNA 365; MICRORNA 378; MICRORNA 484; MICRORNA 625; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOSENSITIZATION; CLINICAL ARTICLE; DCK GENE; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOSCOPIC ECHOGRAPHY; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; GENE; GENE EXPRESSION; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; LONG TERM SURVIVAL; MALE; NAUSEA; NEUTROPENIA; NONVIRAL GENE DELIVERY SYSTEM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEOMICS; PRURITUS; RECOMMENDED DRUG DOSE; SSTR2 GENE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UMK GENE; CLINICAL TRIAL; GENE THERAPY; METABOLISM; MIDDLE AGED; PANCREATIC NEOPLASMS; TISSUE DISTRIBUTION;

AGED; FEMALE; GENETIC THERAPY; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TISSUE DISTRIBUTION;

EID: 84927102567     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.1     Document Type: Article

References (30)

1. Cancer Facts & Figures 2013. .
2. Burris, HA 3rd, Moore, MJ, Andersen, J, Green, MR, Rothenberg, ML, Modiano, MR et al. (1997). Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413.
3. Pancreatic Cancer Action Network. .
4. Moore, MJ, Goldstein, D, Hamm, J, Figer, A, Hecht, JR, Gallinger, S et al.; National Cancer Institute of Canada Clinical Trials Group. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966.
5. Von Hoff, DD, Ervin, T, Arena, FP, Chiorean, EG, Infante, J, Moore, M et al. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369: 1691-1703.
6. Buscail, L, Saint-Laurent, N, Chastre, E, Vaillant, JC, Gespach, C, Capella, G et al. (1996). Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 56: 1823-1827.
7. Carrere, N, Vernejoul, F, Souque, A, Asnacios, A, Vaysse, N, Pradayrol, L et al. (2005). Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. Hum Gene Ther 16: 1175-1193.
8. Vernejoul, F, Faure, P, Benali, N, Calise, D, Tiraby, G, Pradayrol, L et al. (2002). Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res 62: 6124-6131.
9. Rochaix, P, Delesque, N, Esteve, JP, Saint-Laurent, N, Voight, JJ, Vaysse, N et al. (1999). Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum Gene Ther 10: 995-1008.
10. Cordelier, P, Bienvenu, C, Lulka, H, Marrache, F, Bouisson, M, Openheim, A et al. (2007). Replication-deficient rSV40 mediate pancreatic gene transfer and long-term inhibition of tumor growth. Cancer Gene Ther 14: 19-29.
11. Delesque, N, Buscail, L, Esteve, JP, Saint-Laurent, N, Muller, C, Weckbecker, G et al. (1997). sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res 57: 956-962.
12. Guillermet, J, Saint-Laurent, N, Rochaix, P, Cuvillier, O, Levade, T, Schally, AV et al. (2003). Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci USA 100: 155-160.
13. Benali, N, Cordelier, P, Calise, D, Pages, P, Rochaix, P, Nagy, A et al. (2000). Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci USA 97: 9180-9185.
14. Ohhashi, S, Ohuchida, K, Mizumoto, K, Fujita, H, Egami, T, Yu, J et al. (2008). Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. Anticancer Res 28: 2205-2212.
15. Marechal, R, Bachet, JB, Mackey, JR, Dalban, C, Demetter, P, Graham, K et al. (2012). Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 143: 664-674.e1.
16. Vernejoul, F, Ghenassia, L, Souque, A, Lulka, H, Drocourt, D, Cordelier, P et al. (2006). Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. Mol Ther 14: 758-767.
17. Siegel, R, Naishadham, D and Jemal, A (2013). Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
18. Yachida, S, Jones, S, Bozic, I, Antal, T, Leary, R, Fu, B et al. (2010). Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117.
19. Jones, S, Zhang, X, Parsons, DW, Lin, JC, Leary, RJ, Angenendt, P et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
20. Gourgou-Bourgade, S, Bascoul-Mollevi, C, Desseigne, F, Ychou, M, Bouche, O, Guimbaud, R et al. (2013). Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 31: 23-29.
21. Bournet, B, Migueres, I, Delacroix, M, Vigouroux, D, Bornet, JL, Escourrou, J et al. (2006). Early morbidity of endoscopic ultrasound: 13 years' experience at a referral center. Endoscopy 38: 349-354.
22. Hecht, JR, Farrell, JJ, Senzer, N, Nemunaitis, J, Rosemurgy, A, Chung, T et al. (2012). EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc 75: 332-338.
23. Herman, JM, Wild, AT, Wang, H, Tran, PT, Chang, KJ, Taylor, GE et al. (2013). Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol 31: 886-894.
24. Hanna, N, Ohana, P, Konikoff, FM, Leichtmann, G, Hubert, A, Appelbaum, L et al. (2012). Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer. Cancer Gene Ther 19: 374-381.
25. Anurathapan, U, Chan, RC, Hindi, HF, Mucharla, R, Bajgain, P, Hayes, BC et al. (2014). Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther 22: 623-633.
26. Chmielewski, M, Hahn, O, Rappl, G, Nowak, M, Schmidt-Wolf, IH, Hombach, AA et al. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 143: 1095-1107.e2.
27. Poplin, E, Wasan, H, Rolfe, L, Raponi, M, Ikdahl, T, Bondarenko, I et al. (2013). Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol 31: 4453-4461.
28. Schultz, NA, Dehlendorff, C, Jensen, BV, Bjerregaard, JK, Nielsen, KR, Bojesen, SE et al. (2014). MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 311: 392-404.
29. Chang, SC, Erwin, AE and Lee, AS (1989). Glucose-regulated protein (GRP94 and GRP78) genes share common regulatory domains and are coordinately regulated by common trans-acting factors. Mol Cell Biol 9: 2153-2162.
30. Al Saati, T, Clerc, P, Hanoun, N, Peuget, S, Lulka, H, Gigoux, V et al. (2013). Oxidative stress induced by inactivation of TP53INP1 cooperates with KrasG12D to initiate and promote pancreatic carcinogenesis in the murine pancreas. Am J Pathol 182: 1996-2004.